03:47 PM EDT, 06/12/2024 (MT Newswires) -- Eli Lilly ( LLY ) received approval from the US Food and Drug Administration for selpercatinib to treat thyroid cancer in certain adult and pediatric patients two years and older, the regulator said Wednesday.

The drug is approved for patients with advanced or metastatic thyroid cancer who have RET gene fusion mutation, need systemic therapy and do not respond to radioactive iodine treatment, according to the FDA.

The regulator previously approved selpercatinib for the same indication in patients 12 years and older in 2020.

The expanded approval was reviewed under expedited breakthrough and orphan designations, the FDA added.

Lilly did not immediately respond to MT Newswires' request for comment.

Price: 865.49, Change: -0.34, Percent Change: -0.04